Detalhe da pesquisa
1.
Multiple-ascending doses of ACT-1014-6470, an oral complement factor 5a receptor 1 (C5a1 receptor) antagonist: Tolerability, pharmacokinetics and target engagement.
Br J Clin Pharmacol
; 89(1): 380-389, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36000981
2.
Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women.
J Clin Pharmacol
; 2024 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38736033
3.
Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva - A Case Study.
J Clin Pharmacol
; 2024 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38497339
4.
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects.
Clin Drug Investig
; 43(11): 827-837, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37858005
5.
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT-1014-6470 in vitro and in vivo.
Clin Transl Sci
; 16(7): 1220-1231, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37042126
6.
Modeling time-delayed concentration-QT effects with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist.
Pharmacol Res Perspect
; 11(4): e01112, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37470156
7.
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.
Front Immunol
; 11: 599417, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33362783